Product Review – Venetoclax for first-line and relapsed/refractory CLL

As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Venetoclax for the treatment of first-line and relapsed/refractory chronic lymphocytic leukaemia.

This review discusses indications, pharmacological properties, mechanism of action and major studies featuring Venetoclax. It also provides commentary and recommendations from Professor Stephen Opat and Dr Ross Salvaris.

Please login below to download this issue (PDF)

Subscribe